ADC	antibody–drug conjugate
AGO	Arbeitsgemeinschaft Gynäkologische Onkologie
ASCO	American Society of Clinical Oncology
BOR	best overall response
CHMP	Committee for Medicinal Products for Human Use
ChT	chemotherapy
CrCl	creatinine clearance
DAR	drug-to-antibody ratio
Dato-DXd	datopotamab deruxtecan
DCR	disease control rate
DOR	duration of response
DXd	deruxtecan payload
ESMO	European Society for Medical Oncology
EU	European Union
FDA	U.S. Food and Drug Administration
G-CSF	granulocyte colony-stimulating factor
GR	grade of recommendation
HER2	human epidermal growth factor receptor 2
HR	hormone receptor; hazard ratio
HR+/HER2−	hormone receptor-positive/HER2-negative
ILD	interstitial lung disease
LoE	level of evidence
MCBS	Magnitude of Clinical Benefit Scale
NCCN	National Comprehensive Cancer Network
ORR	objective response rate
OS	overall survival
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed death-ligand 1
PFS	progression-free survival
pp	percentage points
SG	sacituzumab govitecan
SN-38	active metabolite of irinotecan
T-DXd	trastuzumab deruxtecan
TNBC	triple-negative breast cancer
TOP1	topoisomerase I
TROP2	trophoblast cell-surface antigen 2
TTR	time to response
UGT1A1	uridine diphosphate glucuronosyltransferase 1A1